Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross-sectional study

Juncai Tian; Huohuan Tian; Mengzhu Yang; Linhui Yang; Dan Liu

doi:10.1002/hsr2.1507

Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross-sectional study

Health Sci Rep. 2023 Aug 18;6(8):e1507. doi: 10.1002/hsr2.1507. eCollection 2023 Aug.

Authors

Juncai Tian¹, Huohuan Tian¹, Mengzhu Yang¹, Linhui Yang¹, Dan Liu¹

Affiliation

¹ Department of Respiratory and Critical Care Medicine West China Hospital of Sichuan University Chengdu Sichuan China.

Abstract

Objective: To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC).

Methods: The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and clinical outcome was analyzed by survival analysis.

Results: Hyperfibrinogenemia was significantly associated with American Veterans Administration Lung Study Group stage and surgery treatment. The survival analysis indicated that patients with hypefibrinogenemia had worse outcome than patients with normal fibrinogen. Pretreatment serum fibrinogen level was identified as a worse independent survival predictor in young SCLC. The hazard ratio was 1.420 (95% confidence interval: 1.035-1.947).

Conclusions: Pretreatment serum fibrinogen is independent associated with overall survival in patients with young SCLC.

Keywords: overall survival; prognostic factor; serum fibrinogen; small cell lung cancer.